Fulcrum Therapeutics(FULC)2025-02-25 12:05Financial Position - Fulcrum Therapeutics expects to report approximately $240 million in cash, cash equivalents, and marketable securities as of December 31, 2024[4] - The financial results for the fourth quarter and fiscal year ended December 31, 2024, are still being finalized and are subject to change[5] - The audit of Fulcrum's consolidated financial statements for the year ended December 31, 2024, is ongoing[5] - The information provided in the corporate presentation is unaudited and preliminary, lacking comprehensive details on Fulcrum's financial condition[5] - The report does not include all necessary information for a complete understanding of Fulcrum's financial condition[5] Corporate Information - The company is classified as an emerging growth company under the Securities Act[3] - Fulcrum's common stock is traded on the Nasdaq Global Market under the symbol FULC[2] - The company has not elected to use the extended transition period for complying with new financial accounting standards[3] - The information in the report is not deemed "filed" for purposes of the Securities Exchange Act[6] Corporate Presentation - An updated corporate presentation was published on January 13, 2025, which includes preliminary financial information[7]